Citations

Clear

12 citation(s) found for "Patel, Meera".

Infectious Complications and Mortality in Post-Transplant Lymphoproliferative Disorder Following Solid Organ Transplantation: Experiences of 10 Years in a Single Center
Cheema, Asfand Yar , Crilley, Thomas, Adcock, Bridget , Ardila, Valentina, Sheu, Micheal, García, S. Gómez , Majid, Aneela, Orland, Mark D. , Patel, Meera , Garcia, Sofia, Mushtaq, Ali , Majid, Aneela

Mayo Clinic

No container title available | June 25, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6336582/v1 Get It

Abstract Background: Chronic immunosuppression in solid organ transplant recipients leads to B- and T-cell depletion, which increases the risk of somatic driver mutations that drive monoclonal lymphocyte proliferation. Paradoxically, this impairs cellular immunity, leading to increased susceptibility to both bacterial and viral pathogens. Methods: This retrospective cohort study evaluated solid organ transplant recipients diagnosed with post-transplant lymphoproliferative disorder (PTLD) at the Cleveland Clinic Foundation between January 1, 2010, and December 30, 2021. Patients aged ≥18 years with infection data available for at least one-year post-PTLD diagnosis were included, excluding hematopoietic stem cell transplant recipients. Data on PTLD subtype, Epstein-Barr virus (EBV) status, infectious complications, and outcomes were analyzed using univariate analysis (Pearson’s χ² test) and multivariable logistic regression to identify predictors of infections and mortality. Results: Among 98 PTLD cases, the median onset was 7.03 years post-transplant. EBV-positive PTLD had an onset of 6.97 ± 7.21 years, whereas EBV-negative cases occurred later (8.06 ± 5.24 years). Monomorphic PTLD (94.9%), particularly diffuse large B-cell lymphoma (DLBCL, 63.3%), was predominant. Infections occurred in 60% of patients post-PTLD, with bacterial (41.25%), viral (31.66%), fungal (25.9%), and parasitic (1.19%) infections. At one year, infection-related mortality (48%) exceeded PTLD progression-related deaths (36%). Conclusion: PTLD presents with a complex interplay of immunosuppression, malignancy, and infection. Infections, particularly bacterial infections, are major causes of morbidity and mortality. These findings highlight the need for vigilant infectious disease surveillance and tailored interventions to reduce infection-related mortality and improve outcomes in high-risk populations.
Infectious Risk in Multiple Myeloma Patients Undergoing Treatment with Teclistamab
Sheu, Michael , Patel, Meera , Crilley, Thomas, Majeed, Aneela , Majeed, Aneela , Majeed, Aneela , Mushtaq, Ali , Garcia, Sofia Molina , Anwer, Faiz , Asif, Muhammad Anns

Mayo Clinic

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 1959-1959

10.1182/blood-2024-194386 Get It

Introduction Bispecific antibodies (BsAbs) have become a key component of treatment in relapsed/refractory multiple myeloma (MM). However, despite promising response rates demonstrated in clinical trials, BsAbs have been shown to have a distinct adverse event profile including increased risk of infections as compared with conventional treatment regimens. The aim of this study was to explore the infectious risk of MM patients on active treatment with Teclistamab. Methods This was a retrospective study of MM patients treated with Teclistamab at Taussig Cancer Center from December 16th 2022 to March 31st 2024. Patients who completed step up dosing and received at least one dose of Teclistamab at maintenance dose were included in the study. The study period spanned from the date of the first dose of Teclistamab up to 6 months after the last dose of Teclistamab, change in therapy or death. Infections which required inpatient hospitalization occurring during the study period were included in the study. Neutropenia was defined as absolute neutropenia count <1500 cells/uL. Hypogammaglobulinemia was defined as serum IgG levels below 700 mg/dL. Data were collected on baseline patient characteristics, MM disease characteristics, and infection characteristics. The primary endpoint was rate of infections per patient-year. Results A total of 58 MM patients who were treated with Teclistamab at Taussig Cancer Center were screened for the study. 46/58 (79.3%) of those patients met inclusion criteria and were included in the study. Among the 46 patients included in the study, there were 20 infectious episodes that required inpatient hospitalization, occurring among 18 patients. The median age of the 46 patients was 66 with an interquartile range (IQR) of 62-74. Patients had broad exposure to novel agents including proteasome inhibitors (46, 100.0%), immunomodulatory drugs (44, 95.7%) and monoclonal antibodies (44, 95.7%). Other notable treatment exposures included CAR T-cell therapy (15, 32.6%), and autologous stem cell transplant (3, 6.5%). 6/9 (66.7%) of patients who underwent previous CAR T-cell therapy and 2/3 (66.7%) of patients who underwent previous autologous stem cell transplant developed an infection requiring hospitalization. No statistically significant difference was found in patients with infection and prior CAR T-cell therapy or autologous hematopoietic stem cell transplant. The median number of lines of therapy from MM diagnosis to start of Teclistamab therapy was 7 (IQR: 5.5-8). The median time from start of Teclistamab therapy till first infectious episode was 84.5 days (IQR: 27-177). Bacterial infections were most common (12/20, 60%), with the most common organism being Streptococcus spp. (2/12, 17%). The most common source of infection was respiratory (10/20, 50%). Neutropenia was present at diagnosis for 5/20 (25%) infectious episodes with 4/5 (80%) of these episodes having Grade 4 neutropenia. Hypogammaglobulinemia occurred during the study period in 43/46 (93.5%) patients with a median IgG nadir of 168 (IQR: 118-320). 22/43 (51.2%) patients received intravenous immunoglobulin (IVIG) during the study period, with 3/22 (13.6%) of these patients going on to develop an infection that required inpatient hospitalization. Of the 21 patients not administered IVIG, 13/21 (61.9%) went on to develop an infection that required inpatient hospitalization (p-value .0016). The median length of hospital stay for all infectious episodes was 7.5 days (IQR: 4-12.5). 6/20 (30%) infectious episodes required ICU stay with a median length of stay of 4.5 days (IQR: 2-18). The overall rate of infections per patient-year was 0.82. The rate of infections per patient-year for the 22 patients with hypogammaglobulinemia who did receive IVIG was .28. The rate of infections per patient-year for the 21 patients with hypogammaglobulinemia who did not receive IVIG was 1.5 (p-value = .06). The overall infection-related mortality rate was 3/20 (15%). Conclusion Multiple myeloma patients treated with Teclistamab experienced a high rate of infections requiring hospitalization and ICU care while on active treatment regardless of prior CAR T-cell and autologous hemopoietic stem cell transplant. Preventive measures, such as administration of prophylactic IVIG to patients with hypogammaglobulinemia, improved outcomes and should be taken to reduce infectious risk in this susceptible patient population.
Rapid response of lichen planus to baricitinib associated with suppression of cytotoxic CXCL13+CD8+ T cells
Kechter, Jacob , Do, Tran , Hughes, Alysia N., Zhang, Nan , Bogle, Rachael , Brumfiel, Caitlin M. , Boudreaux, Blake , Bhullar, Puneet , Nassir, Shams , Yousif, Miranda , Stockard, Alyssa , Leibovit-Reiben, Zachary , Ogbaudu, Ewoma , DiCaudo, David J. , Fox, Jennifer, Xing, Xianying , Zunich, Samantha , Branch, Emily, Billi, Allison C. , Pittelkow, Mark R. , Mangold, Aaron R. , Stockard, Alyssa , Hwang, Angelina S , Kechter, Jacob A, Patel, Meera H. , Yousif, Miranda L, Stockard, Alyssa L, Fox, Jennifer , Mangold, A R , Billi, Allison C , Hwang, Angelina , Li, Xing , Wasikowski, Rachael, Patel, Meera , Leibovit‐Reiben, Zachary , Gharaee‐Kermani, Mehrnaz , Kahlenberg, J. Michelle , Plazyo, Olesya , Tsoi, Lam C. , Gudjonsson, Johann E

Mayo Clinic

Journal of Clinical Investigation | November 14, 2024 | Volume: 135 | Issue: 2 | Pages: No page available

10.1172/jci179436 | PMID 39541169 Get It

BACKGROUND Cutaneous lichen planus (LP) is a recalcitrant, difficult-to-treat, inflammatory skin disease characterized by pruritic, flat-topped, violaceous papules on the skin. Baricitinib is an oral Janus kinase (JAK) 1/2 inhibitor that interrupts the signaling pathway of IFN-γ, a cytokine implicated in the pathogenesis of LP. METHODS In this phase II trial, 12 patients with cutaneous LP received 2 mg daily baricitinib for 16 weeks, accompanied by in-depth spatial, single-cell, and bulk transcriptomic profiling of pre- and posttreatment samples. RESULTS An early and sustained clinical response was seen, with 83.3% of patients responsive at week 16. Our molecular data identified a unique, oligoclonal IFN-γ, CD8 + , and CXCL13 + cytotoxic T cell population in LP skin and demonstrated a rapid decrease in IFN signature within 2 weeks of treatment, most prominently in the basal layer of the epidermis. CONCLUSION This study demonstrates the efficacy and molecular mechanisms of JAK inhibition in LP. TRIAL REGISTRATION NCT05188521 FUNDING Eli Lilly, Appignani Benefactor Funds, 5P30AR075043, Mayo Clinic Clinical Trials Stimulus Funds.
Calcitonin Gene-Related Peptide Inhibitor Use for Migraine Associated with Exacerbation of Raynaud Phenomenon (1885)
Breen, Ilana, Brumfiel, Caitlin M. , Patel, Meera H. , Griffing, Leroy, Pittelkow, Mark R. , VanderPluym, Juliana H. , Mangold, Aaron R.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 96 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.96.15_supplement.1885 Get It

Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis
Boudreaux, Blake , Pincelli, Thaís , Bhullar, Puneet , Patel, Meera H. , Brumfiel, Caitlin M. , Li, Xing , Heckman, Michael G. , Pittelkow, Mark R. , Mangold, Aaron R. , Sluzevich, Jason C. , Boudreaux, Blake W , Pincelli, T , Bhullar, Puneet K , Mangold, A R , Heckman, Michael G , Pittelkow, Mark R , Sluzevich, Jason C

Mayo Clinic

British Journal of Dermatology | June 15, 2022 | Volume: 187 | Issue: 5 | Pages: 650-658

10.1111/bjd.21708 | PMID 35701384 Get It

Abstract Background The pathogenesis of pityriasis rubra pilaris (PRP) is not completely understood, but interleukin (IL)-17 has been shown to play a critical role. There are no reliable immunomodulatory agents to treat PRP. We conducted an open-label, single-arm clinical trial of secukinumab, a monoclonal antibody that inhibits IL-17A, for the treatment of PRP. Objectives To evaluate the clinical efficacy of secukinumab and define the transcriptomic landscape of PRP and its response to IL-17A blockade. Methods Twelve patients with PRP were recruited for an open-label trial of secukinumab. Patients received a 24-week course of secukinumab. The primary endpoint was a ≥ 75% reduction in Psoriasis Area and Severity Index (PASI 75) from baseline to week 28. Secondary endpoints included PASI 90, change in Physician’s Global Assessment (PGA), and change in Dermatology Life Quality Index (DLQI). RNA sequencing was performed on lesional and nonlesional skin biopsies obtained at baseline and week 2. Sample groups were compared to identify differential gene expression and pathway enrichment. This trial was registered with ClinicalTrials.gov: ‘Cosentyx (secukinumab) for the treatment of adult onset pityriasis rubra pilaris’ – NCT03342573. Results At week 28, six of 11 patients (55%) achieved PASI 75, and three patients (27%) achieved PASI 90. PGA (P = 0.008) and DLQI scores (P = 0.010) showed significant improvement with treatment. No serious treatment-related adverse events were encountered. Treatment with secukinumab normalized transcriptional differences between lesional and nonlesional skin. Transcriptomic data from nonresponsive patients suggest that overactivity of innate immune pathways may be driving resistance to secukinumab. Conclusions Secukinumab appears to be an effective treatment for PRP and warrants further investigation. PRP is a transcriptionally heterogeneous disease, reflecting its variable response to therapy. Agents targeting other IL-17 isoforms and innate immune mediators should be considered for future clinical trials. What is already known about this topic? The pathogenesis of pityriasis rubra pilaris is incompletely understood. Successful treatment has been reported with a variety of immunomodulatory agents, but disease is often refractory to therapy.Interleukin (IL)-17 is thought to drive keratinocyte proliferation and vascular dysfunction in this disease.A previous trial demonstrated efficacy of the anti-IL-17A drug ixekizumab for pityriasis rubra pilaris. What does this study add? Herein we describe the findings of a clinical trial of secukinumab, an anti-IL-17A monoclonal antibody, for the treatment of pityriasis rubra pilaris.Secukinumab was effective in treating pityriasis rubra pilaris.Our transcriptomic data give new insight into the expressional changes that occur in response to secukinumab and suggest mechanisms of treatment resistance.
Histopathologic features of necrobiosis lipoidica
Johnson, Emma F. , Patel, Meera H. , Brumfiel, Caitlin M. , Severson, Kevin J. , Bhullar, Puneet , Boudreaux, Blake , Butterfield, Richard , DiCaudo, David J. , Nelson, Steven A. , Pittelkow, Mark R. , Mangold, Aaron R. , Johnson, Emma , Mangold, A R

Mayo Clinic

Journal of Cutaneous Pathology | April 11, 2022 | Volume: 49 | Issue: 8 | Pages: 692-700

10.1111/cup.14238 | PMID 35403265 Get It

AbstractBackgroundNecrobiosis lipoidica (NL) is an uncommon granulomatous dermatosis that can occur in patients with or without associated diabetes mellitus (DM). Prior studies have attempted to determine distinctive histopathologic features of NL in patients with and without DM.MethodsA retrospective review of 97 patients with NL was performed to determine the similar and distinctive histopathologic features in patients with DM and without DM.ResultsOf the 97 patients, 32% (n = 31) had DM. Epidermal acanthosis was seen more commonly in diabetics than nondiabetics (32.3% vs. 12.1%; p = 0.017). Naked (sarcoidal/tuberculoid) granulomas were more frequently observed in nondiabetics than diabetics (22.7% vs. 3.2%; p = 0.016). Eosinophils were more common in nondiabetics than diabetics (38.5% vs. 9.7%; p = 0.004), while neutrophilic infiltration was more common in diabetics than nondiabetics (45.2% vs. 17.5%; p = 0.004).ConclusionsThis study corroborates well‐documented histopathologic features of NL and shows distinctive histopathologic features of NL among patients with DM‐I, DM‐II, and without DM. These results support the hypothesis that there are different underlying drivers of NL between diabetics and nondiabetics.
Consolidation of US dermatology practices
Puri, Pranav , Patel, Meera H. , Brumfiel, Caitlin M. , Pittelkow, Mark R. , Mangold, Aaron R. , Mangold, A R , Puri, P

Mayo Clinic

International Journal of Dermatology | December 3, 2021 | Volume: 61 | Issue: 12 | Pages: No page available

10.1111/ijd.16017 | PMID 34859886 Get It

Recurrence of primary cutaneous CD30-positive lymphoproliferative disorder following COVID-19 vaccination
Brumfiel, Caitlin M. , Patel, Meera H. , DiCaudo, David J. , Pittelkow, Mark R. , Mangold, Aaron R. , Rosenthal, Allison , Pittelkow, Mark R , Mangold, A R

Mayo Clinic

Leukemia & Lymphoma | May 11, 2021 | Volume: 62 | Issue: 10 | Pages: 2554-2555

10.1080/10428194.2021.1924371 | PMID 33974494 Get It

Evaluation of the Safety of Calcitonin Gene-Related Peptide Antagonists for Migraine Treatment Among Adults With Raynaud Phenomenon
Breen, Ilana, Brumfiel, Caitlin M. , Patel, Meera H. , Butterfield, Richard , VanderPluym, Juliana H. , Griffing, Leroy, Pittelkow, Mark R. , Mangold, Aaron R. , Breen, Ilana D, Mangold, A R , VanderPluym, Juliana

Mayo Clinic

JAMA Network Open | April 20, 2021 | Volume: 4 | Issue: 4 | Pages: e217934

10.1001/jamanetworkopen.2021.7934 | PMID 33871613 Get It

The prognostic value of inositol polyphosphate 5‐phosphatase in cutaneous squamous cell carcinoma in the general population
Patel, Meera H. , Brumfiel, Caitlin M. , Severson, Kevin J. , DiCaudo, David J. , Nelson, Steven A. , Butterfield, Richard , Zhang, Nan , Baum, Christian L. , Mangold, Aaron R. , Baum, Christian, Sekulic, Aleksander , Mangold, A R

Mayo Clinic

International Journal of Dermatology | April 16, 2021 | Volume: 60 | Issue: 10 | Pages: No page available

10.1111/ijd.15565 | PMID 33860939 Get It